Pretreatment follicle-stimulating hormone: a prognostic serum marker of spermatogenesis status in patients treated for germ cell cancer.
OBJECTIVE
We evaluate the use of pretreatment follicle-stimulating hormone (FSH) in patients with germ cell tumors as a prognostic serum marker of spermatogenesis after standard treatment. Additionally, Leydig cell function was investigated by estimation of luteinizing hormone (LH) and testosterone (T), and calculation of the T/LH ratio.


METHODS
Serum FSH, LH and T were determined radioimmunologically associated with semen analyses in 20 patients with seminoma (pathological stages IA to IIB) after unilateral orchiectomy before and up to 24 months after infradiaphragmatic radiotherapy. Additionally, hormone analyses were performed in 18 patients with nonseminomatous germ cell tumor (pathological stages IIA to C) before and up to 36 months after standard cisplatin based chemotherapy.


RESULTS
Seminoma patients undergoing radiotherapy were divided into 2 groups consisting of 12 patients with normal pretreatment serum FSH and 8 with elevated FSH reflecting spermatogenesis deficits even before treatment. Six months after irradiation a significant increase in FSH (p <0.01) associated with a decrease in sperm density was observed in both groups and 24 months after radiotherapy patients with initially normal FSH had significantly lower serum FSH (p <0.01) associated with higher sperm density than those with initially elevated FSH (p <0.01), indicating less impairment of Sertoli cell function. Comparable results were observed in chemotherapy treated germ cell tumor patients with initially normal (11) and elevated serum FSH (7), respectively, and 36 months after chemotherapy patients with initially normal FSH had significantly lower FSH concentrations than those with initially elevated FSH (p <0.01). Compensated impairment of Leydig cell function reflected by a subnormal T/LH ratio was evident before chemotherapy in 16.7% of patients increasing up to 41.2% 36 months after therapy. In contrast, 24 months after radiotherapy only 25% of seminoma patients showed a subnormal ratio reflecting less damage to the Leydig cells caused by irradiation.


CONCLUSIONS
Pretreatment FSH is a prognostic serum marker of spermatogenesis status of germ cell tumor patients receiving standard radiotherapy or chemotherapy. In contrast to seminoma patients after radiotherapy, impairment of Leydig cell function was evident in germ cell tumor patients after cisplatin based chemotherapy.
Brennemann
W
W
Department of Clinical Biochemistry, University of Bonn, Germany.
Stoffel-Wagner
B
B
Wichers
M
M
Helmers
A
A
Albers
P
P
Mezger
J
J
Klingmüller
D
D
D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D015592:Immunoradiometric Assay; D007985:Leydig Cells / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009919:Orchiectomy; D011379:Prognosis; D018239:Seminoma / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy; D013091:Spermatogenesis; D013736:Testicular Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy; D013739:Testosterone / Q000097:blood
D014408:Biomarkers, Tumor; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone